FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

Study ID
NCT02827201

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

FIRGEMAX

Trial Summary

The main objective of this trial is to evaluate every 2 months alternating nab-paclitaxel/gemcitabine and FOLFIRI.3 versus nab-paclitaxel + gemcitabine, regarding the progression of disease at 6 months.

More informations

Trial Starting Date

Nov 30,2015

Requirements

Gender All
Minimum age 18 Years
Maximum age 75 Years

Enrollement Limit

127